Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

CNS Pharmaceuticals Inc

Healthcare US CNSP

4.34USD
0.06(1.40%)

Last update at 2026-06-23T16:36:00Z

Day Range

4.254.35
LowHigh

52 Week Range

2.0616.56
LowHigh

Fundamentals

  • Previous Close 4.28
  • Market Cap2.00M
  • Volume6170
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-15.98264M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-35.75

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -15.85056M -14.85780M -18.85123M -15.27413M -14.03658M
Minority interest - - - - -
Net income -15.85056M -14.85780M -18.85123M -15.28116M -14.04586M
Selling general administrative 6.21M 5.61M 4.77M 5.97M 4.68M
Selling and marketing expenses - - 0.00413M - -
Gross profit - -0.00331M -0.00413M - -
Reconciled depreciation 0.00392M 0.00331M 0.00556M 0.01M 0.01M
Ebit -15.83533M -14.84168M -18.86511M -15.26711M -14.02729M
Ebitda -15.83142M -14.83837M -18.86097M -15.25535M -14.01422M
Depreciation and amortization 0.00392M 0.00331M 0.00413M 0.01M 0.01M
Non operating income net other - - - - -
Operating income -15.98656M -14.90194M -18.86511M -15.26711M -14.02729M
Other operating expenses 15.99M 14.90M 18.87M 15.27M 14.03M
Interest expense 0.02M 0.02M 0.01M 0.00703M 0.00928M
Tax provision - - - - -
Interest income 0.15M 0.06M 0.03M - -
Net interest income 0.14M 0.04M 0.00745M -0.00703M -0.00928M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - -0.00000M 0.00703M 0.00928M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 15.99M 14.90M 18.86M 15.27M 14.03M
Cost of revenue - 0.00331M 0.00413M - -
Total other income expense net 0.14M 0.04M 0.01M -0.00703M -0.00928M
Discontinued operations - - - - -
Net income from continuing ops -15.85056M -14.85780M -18.61283M -15.27413M -14.03658M
Net income applicable to common shares - - - - -14.03658M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 8.62M 8.70M 1.70M 13.05M 8.76M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.90M 1.31M 0.84M 2.51M 2.47M
Total liab 4.10M 2.52M 6.13M 4.92M 2.14M
Total stockholder equity 4.52M 6.18M -4.43211M 8.13M 6.62M
Deferred long term liab - - - - 0.33M
Other current liab 3.77M 2.20M 5.83M 0.83M 0.22M
Common stock 0.00063M 0.00141M 0.00621M 0.00162M 0.03M
Capital stock 0.00063M 0.00141M 0.00621M 0.00162M 0.03M
Retained earnings -100.27527M -84.42470M -69.56690M -50.71568M -34.98292M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.00000M - 1.26M
Cash 7.20M 6.46M 0.55M 10.06M 5.00M
Cash and equivalents - - - - -
Total current liabilities 4.10M 2.52M 6.13M 4.92M 2.14M
Current deferred revenue - - -5.83216M - -
Net debt -6.87244M -6.13531M -0.24791M -9.64544M -4.61672M
Short term debt 0.33M 0.33M 0.30M 0.41M 0.39M
Short long term debt 0.33M 0.33M 0.30M 0.41M 0.39M
Short long term debt total 0.33M 0.33M 0.30M 0.41M 0.39M
Other stockholder equity 104.80M 90.60M 65.13M 58.85M 41.58M
Property plant equipment - - - - 0.02M
Total current assets 8.10M 8.66M 1.39M 12.56M 7.48M
Long term investments - - - - -
Net tangible assets - - - - 6.62M
Short term investments - - - - -
Net receivables 0.00000M 0.88M - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable - 2.20M 5.83M 3.68M 1.52M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.50M 0.04M 0.31M 0.48M 1.26M
Deferred long term asset charges - - - - -
Non current assets total 0.52M 0.04M 0.31M 0.49M 1.28M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.00419M -0.00174M -0.00442M -0.00575M
Change to liabilities - - - - 0.58M
Total cashflows from investing activities -0.01818M -0.00419M -0.00390M - -0.00575M
Net borrowings -0.29755M -0.30081M -0.43873M - -0.47749M
Total cash from financing activities 14.57M 23.03M 4.64M 15.61M 4.51M
Change to operating activities - - - - -1.81514M
Net income -15.85056M -14.85780M -18.85123M -15.27413M -14.03658M
Change in cash 0.74M 5.91M -9.50669M 5.05M -9.03498M
Begin period cash flow 6.46M 0.55M 10.06M 5.00M 14.04M
End period cash flow 7.20M 6.46M 0.55M 10.06M 5.00M
Total cash from operating activities -13.81111M -17.11330M -14.14003M -10.55781M -13.53831M
Issuance of capital stock 14.05M 23.38M 7.51M 16.04M 4.65M
Depreciation 0.00392M 0.00331M 0.00413M 0.01M 0.01M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock -0.00204M 0.00000M - - -
Other cashflows from financing activities 0.82M -0.04543M 2.76M 0.00273M 0.33M
Change to netincome - - - - 1.72M
Capital expenditures 0.02M 0.00419M 0.00390M 0.00442M 0.00575M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.85M -3.69387M 3.70M 3.16M -1.23864M
Stock based compensation 0.19M 0.84M 1.01M 1.20M 1.72M
Other non cash items 0.00256M 0.60M 0.00050M 0.34M 7.01M
Free cash flow -13.82928M -17.11749M -14.14393M -10.56224M -13.54406M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
CNSP
CNS Pharmaceuticals Inc		 0.06 1.40% 4.34 - - - 0.47 0.40
NVO
Novo Nordisk A/S		 1.54 3.36% 47.42 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.63 0.35% 468.42 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.53 0.90% 618.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company's drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.

CNS Pharmaceuticals Inc

2100 West Loop South, Houston, TX, United States, 77027

Key Executives

Name Title Year Born
Mr. John Michael Climaco Esq., J.D. Chairman, CEO & Pres 1969
Mr. Christopher S. Downs CPA, CTP, FP&A Chief Financial Officer 1978
Dr. Sandra L. Silberman M.D., Ph.D. Chief Medical Officer 1955
Dr. Waldemar Priebe Ph.D. Founder NA
Dr. Donald H. Picker Ph.D. Chief Science Officer 1946
Mr. John Michael Climaco Esq., J.D. CEO, President & Director 1969
Mr. Christopher S. Downs C.P.A., CTP, FP&A Chief Financial Officer 1979
Dr. Sandra L. Silberman M.D., Ph.D. Chief Medical Officer 1956
Mr. Christopher S. Downs CPA, CTP, FP&A Senior Vice President of Finance 1979
Mr. Rami Levin M.B.A. President, CEO & Director 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.